The company, however, did not disclose financial details of the licensing agreement.
Glenmark Pharma said in April 2019 it had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing phase-3 clinical trials in which the drug demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin.
Subsequently, Glenmark launched Remogliflozin, indicated in the treatment of Type 2 Diabetes Mellitus in adults under the brand names 'Remo' and 'Remozen'.
"The burden of diabetes in India is growing at an alarming rate and through this collaboration, we aim to improve access to the latest, novel and globally- researched sodium glucose co-transporter-2 (SGLT2) inhibitor by providing an effective, high quality and world-cass treatment option to patients in India," Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.
"This partnership will also lay the foundation for a long term collaboration with Torrent for Remogliflozin in terms of its additional line extensions and further clinical development,' he added.
Dhruv Gulati, Executive Director (India & ROW), Torrent Pharma, said, "The drug will augment the Type 2 Diabetes Mellitus treatment armamentarium in the country and this partnership will be an important step towards enhancing access to the growing needs of diabetic patients.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.